Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience.

By I. Katzan, A. Furlan, L. Lloyd, J. Frank, D. Harper, J. Hinchey, J. Hammel, Annie Qu, C. Sila. Journal of the American Medical Association (JAMA), 2000

707 citations recorded by the source corpus.

Subfields: Cancer Research, Epidemiology, Neurology

View Paper: https://www.semanticscholar.org/paper/62fc20a8407d5c587673dea8a85e4118bdb9a16c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

Alejandro Rabinstein

In Neurology

Citations in the corpus

Recommendations for the establishment of primary stroke centers (2000, methodology): “7%, but for 50% of treated patients, national treatment protocol criteria were violated.(8) In another multicenter study, the rate of intracranial hemorrhage following tPA administration was 3.”
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association (2013, background): “hospital mortality among intravenous rtPA–treated stroke patients.(118,119) In the case of the Cleveland, OH, experience,”
Practice-based research--"Blue Highways" on the NIH roadmap. (2007, background): “After initial widespread use of tissue plasminogen activator for acute ischemic stroke, several studies reported significant deviation from national treatment recommendations leading to unacceptably high complication rates.(14) Physicians and care teams involved in randomized trials are often the be”
Repairing the human brain after stroke: I. Mechanisms of spontaneous recovery (2008, background): “Only 2% to 3% of patients with stroke receive intravenous tissue plasminogen activator.(204,205) However, a substantially greater proportion of patients may reach medical attention in time to be eligible for an effective restorative therapy given that the time window in preclinical studies is genera”
Protein therapeutics: a summary and pharmacological classification (2008, background): “Alteplase (recombinant tissue plasminogen activator (tPA; also known as PLAT)), is used to treat life-threatening blood clots in conditions such as coronary artery occlusion, acute ischaemic stroke and pulmonary embolis”